Hexokinase 2 (HK2) and pyruvate kinase M2 (PKM2), the rate-limiting enzymes of cellular glycolysis, are remarkably upregulated in glioma, colorectal cancer, and liver cancer, promoting glycolysis and have been generally accepted as key factors in the reprogramming of glucose metabolism [24–26]. Here, HK2 is linked to central nervous system cancer.